ArriVent BioPharma, Inc. (AVBP)

NASDAQ: AVBP · Real-Time Price · USD

20.92

+0.10 (0.48%)

Apr 28, 2025, 4:00 PM EDT - Market closed

ArriVent BioPharma Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Selling, General & Admin	15.3	9.71	6.47	3.02
Research & Development	79	64.88	30.43	8.58
Operating Expenses	94.31	74.59	36.91	11.59
Operating Income	-94.31	-74.59	-36.91	-11.59
Interest & Investment Income	13.82	5.26	-	-
EBT Excluding Unusual Items	-80.49	-69.33	-36.91	-11.59
Pretax Income	-80.49	-69.33	-36.91	-68.81
Net Income	-80.49	-69.33	-36.91	-68.81
Net Income to Common	-80.49	-69.33	-36.91	-68.81
Shares Outstanding (Basic)	31	2	1	1
Shares Outstanding (Diluted)	31	2	1	1
Shares Change (YoY)	1369.88%	67.64%	79.57%	-
EPS (Basic)	-2.56	-32.38	-28.90	-96.75
EPS (Diluted)	-2.56	-32.38	-28.90	-96.75
EBIT	-94.31	-74.59	-36.91	-11.59

Updated Mar 3, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q